Graduate
Martin Carroll has been named to the board of directors of Catalent, a biotech firm in Somerset, N.J. He was head of corporate strategy and development for Boehringer Ingelheim, from which he retired in 2013. He had joined the organization in 2002 as president of Boehringer Pharmaceuticals. Martin also is a director of Mallinckrodt Pharmaceuticals and chairs its compliance committee.